Earnings call · Jun 2026 (H1 FY26)

Scinai Immunotherapeutics H1 FY26 earnings call SCNI

Aug 26, 2026 Source

Executive summary

Scinai Immunotherapeutics H1 FY26 — CDMO Expansion and Execution Focus

Scinai Immunotherapeutics presented its H1 FY26 results in a corporate overview webinar, highlighting a significant transformation driven by the acquisition of Recipharm's Yavne operations. The company is now focused on executing its expanded two-platform strategy, converting customer activity into revenue, increasing CDMO utilization, and advancing its R&D pipeline with capital discipline. Management emphasized that while reported net income was positive due to an accounting gain, the underlying business generated an operating loss, necessitating a combination of operational execution and selective financing to strengthen liquidity.

Highlights

H1 FY26 revenue increased to $949,000 from $773,000 in H1 FY25.
Reported net income of $1.57 million for H1 FY26, primarily due to a $6.4 million bargain purchase gain from the Recipharm acquisition.
Committed customer orders totaled $3.1 million as of August 16, with activity distributed almost equally between Jerusalem and Yavne CDMO sites.
Received $650,000 in cash payments and advances post-June 30 from an expanded U.S. manufacturing engagement.

Concerns

Reported a gross loss of $2.37 million and an operating loss of $4.6 million for H1 FY26 due to the expanded CDMO footprint's fixed costs before full utilization.
Cash and restricted cash stood at $2.85 million as of June 30, 2026, with the company acknowledging the need for additional capital.
The underlying business still generated an operating loss during the period despite the reported net income.

Guidance & targets

Category	Target	Timeline	Confidence
CDMO revenue	$5 million high materiality	FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
CDMO - Jerusalem Focuses on biologics development, analytical services, aseptic processing, and clinical cGMP manufacturing. Committed customer orders: $1.5 million (as of Aug 16, 2026)	—	—	—	—
CDMO - Yavne Acquired operations adding early chemistry development and small-scale cGMP manufacturing of API for clinical programs. Committed customer orders: $1.6 million (as of Aug 16, 2026)	—	—	—	—

Deals & partnerships

Recipharm Acquisition of former Recipharm operations in Yavne, Israel

The transaction significantly expanded Scinai's commercial side, broadening its capabilities in early chemistry development and small-scale cGMP manufacturing of API.

Recipharm AB Commercial collaboration

Recipharm AB was the international CDMO company that sold the Recipharm Israel facility and business to Scinai.

PINCEL Option agreement for PC-111

PC-111 is being advanced under this option agreement, focusing on serious dermatology conditions.

Risks & headwinds

Expanded CDMO cost base H1 FY26

Gross loss of $2.37 million and operating loss of $4.6 million in H1 FY26

Mitigation:Increasing utilization of infrastructure and workforce, converting customer activity into revenue.

Need for additional capital Near term

Cash and restricted cash of $2.85 million as of June 30, 2026

Mitigation:Combination of operational execution, sales, disciplined financing, non-dilutive funding, and selective use of capital market tools like SEPA.

Dilution from equity financing Ongoing

Any actual issuance of new equity is dilutive

Mitigation:Management controls whether and when to use the SEPA facility, sizing draws responsibly, and pursuing non-dilutive funding and cash generation from CDMO business.

What to watch next

CDMO customer commitments to revenue conversion

H2 FY26

Current $3.1 million committed customer orders (of which $1 million uninvoiced as of Aug 10)

Target Meaningful amount of customer work converted into recognized revenue

Why it matters

Demonstrates successful execution of the expanded commercial platform and progress towards the $5 million CDMO revenue target.

For me, successful execution by year-end would mean several things. First, converting meaningful amount of customer work into recognized revenue.

Q&A highlights

Clarification on the $15 million F-1 registration statement update and potential dilution.

Management clarified that the F-1 update was a normal post-effective amendment reflecting existing SEPA terms and recent financial info, not a new $15 million financing or an obligation to draw the full amount. They control the timing and size of draws, which are priced at 97% of VWAP without warrants, viewing it as one flexible financing tool.

“Absolutely not. The filing updates the registration statement that we already had underlying our existing SEPA to reflect our June 30 financial information. This is a post-effective amendment, it's very normal. It doesn't basically mean that we are going to raise $15 million tomorrow through this instrument.”

asked by Andrew Eriksen · answered by Amir Reichman

2 min read 6 chapters

Detailed narrative

Transformation and Expanded CDMO Platform

Scinai underwent a significant transformation in H1 2026, expanding its commercial capabilities through the acquisition of former Recipharm operations in Yavne, Israel. This added an experienced team, quality systems, technical know-how, and customer relationships, creating two complementary platforms: immunology R&D and a broader two-site CDMO business (Jerusalem and Yavne). The focus has shifted from integration to execution and commercialization.

Financial Performance and Accounting Nuances

H1 FY26 revenue was $949,000, up from $773,000 in H1 FY25. However, the expanded CDMO footprint led to a gross loss of $2.37 million and an operating loss of $4.6 million. A non-cash bargain purchase gain of $6.4 million from the Recipharm transaction resulted in a reported net income of $1.57 million, which management clarified does not reflect operating profitability.

CDMO Capabilities and Commercial Strategy

The Jerusalem site focuses on biologics development, analytical services, aseptic processing, and clinical cGMP manufacturing. The Yavne site adds early chemistry development and small-scale cGMP manufacturing of active pharmaceutical ingredients (API). Management emphasizes leveraging the acquired team and systems to increase utilization, build longer-term customer relationships, and convert customer activity into revenue.

Committed Customer Orders and Revenue Recognition

As of August 16, Scinai had $3.1 million in committed customer orders, defined as signed, usually non-cancelable purchase orders with upfront payments. Approximately $1.6 million relates to Yavne and $1.5 million to Jerusalem. Of this, $2.1 million had been invoiced by August 10, with $1 million representing uninvoiced work. This metric indicates commercial activity but is not a direct forecast of future revenue due to accounting recognition criteria.

R&D Prioritization and Capital Discipline

On the R&D side, the company is prioritizing programs and maintaining capital discipline. They are evaluating programs based on science, product profile, development feasibility, differentiation, technical risk, and financing needs. The strategy involves seeking non-dilutive funding, collaborations, and strategic partnerships to finance development, rather than relying solely on shareholder capital.

Liquidity and Financing Strategy

As of June 30, 2026, cash and restricted cash totaled $2.85 million, and the company acknowledges the need for additional capital. The financing strategy combines operational execution (expanding customer base, increasing committed orders, efficient project execution), improving working capital efficiency (advances, milestone payments), disciplined spending, non-dilutive funding (grants), and selective use of capital market tools like the SEPA.

AI-generated summary of the company's earnings call. Not investment advice.